Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems

Exclusion Criteria

• •Individuals with health conditions and therapies that may affect immune responses and levels of inflammatory markers, including allergic rhinitis, aspirin/NSAID therapy, asthma, immunodeficiency (HIV or other), Guillain-Barre Syndrome, COPD, or fever/respiratory illness within 30 days prior to entry into study (self-reported).
• •Pregnant or nursing female participants (self-reported on telephone screener, pregnancy test on Visit#1)
• •Unable to communicate in English.
• •Unable or unwilling to follow protocol requirements.
• •Self-report having active, untreated medical/psychiatric conditions.
• •History of serious side effects from nicotine or from any nicotine replacement therapies.
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Vulnerable populations, such as cognitively impaired adults, individuals who are not yet adults, pregnant women, and prisoners.
• •Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug.
• •After receiving information about the NYS flavor ban, participants who report that they are thinking about quitting or stop using their flavor within the next 90 days.